Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Nicotinate
Drug ID BADD_D01563
Description Niacin is a B vitamin used to treat vitamin deficiencies as well as hyperlipidemia, dyslipidemia, hypertriglyceridemia, and to reduce the risk of myocardial infarctions.[L7550,L7553,L7556,L7559,L7562,L7565]
Indications and Usage For the treatment of type IV and V hyperlipidemia. It is indicated as ajunctive therapy.
Marketing Status Prescription; Discontinued
ATC Code C04AC01; C10AD02
DrugBank ID DB00627
KEGG ID D00049
MeSH ID D009525
PubChem ID 937
TTD Drug ID Not Available
NDC Product Code 59651-018; 65162-322; 71740-001; 65372-1194; 47335-539; 59746-387; 51552-0559; 0074-3265; 59746-380; 68180-222; 0074-3275; 62175-322; 62331-016; 62704-0027; 33342-187; 59651-020; 72919-420; 47335-614; 68180-221; 68180-223; 25441-0095; 0074-3274; 50268-584; 71740-201; 71741-020; 71741-047; 51407-268; 59746-381; 47335-613; 62175-320; 33342-189; 51407-267; 59651-019; 63629-7193; 65162-321; 65162-323
Synonyms Niacin | Nicotinic Acid | 3-Pyridinecarboxylic Acid | 3 Pyridinecarboxylic Acid | Niacin Lithium Salt, Hemihydrate | Niacin Potassium Salt | Potassium Salt, Niacin | Niacin Sodium Salt | Sodium Salt, Niacin | Niacin Tartrate | Tartrate, Niacin | Niacin Copper (2+) Salt | Niacin Hydrochloride | Hydrochloride, Niacin | Niacin Iron (2+) Salt | Niacin Tosylate | Tosylate, Niacin | Niacin Zinc Salt | Nicamin | Nico-400 | Nico 400 | Nico400 | Nicobid | Nicocap | Nicolar | Nicotinate | Wampocap | Enduracin | Induracin | Niacin Calcium Salt | Lithium Nicotinate | Nicotinate, Lithium | Niacin Aluminum Salt | Aluminum Salt, Niacin | Niacin Ammonium Salt | Niacin Lithium Salt | Niacin Cobalt (2+) Salt | Niacin Magnesium Salt | Niacin Manganese (2+) Salt
Chemical Information
Molecular Formula C6H4NO2-
CAS Registry Number 59-67-6
SMILES C1=CC(=CN=C1)C(=O)[O-]
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Shock24.06.02.002--Not Available
Skin discolouration23.03.03.005--Not Available
Skin disorder23.03.03.007--Not Available
Skin exfoliation23.03.07.003--Not Available
Skin hyperpigmentation23.05.01.003--
Skin ulcer23.07.03.003; 24.04.03.007--
Somnolence19.02.05.003; 17.02.04.006--
Stomatitis07.05.06.005--
Syncope17.02.04.008; 02.01.02.008; 24.06.02.012--
Tachycardia02.03.02.007--Not Available
Tension19.06.02.005--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Tongue disorder07.14.01.002--Not Available
Tongue oedema10.01.05.008; 07.14.02.007; 23.04.01.009--Not Available
Urinary retention20.02.02.011--
Urticaria23.04.02.001; 10.01.06.001--
Vaginal infection21.14.02.002; 11.01.10.002--
Vaginal inflammation21.14.02.001--
Vertigo04.04.01.003; 17.02.12.002--
Vision blurred17.17.01.010; 06.02.06.007--
Visual impairment06.02.06.008--Not Available
Vomiting07.01.07.003--
Xanthoma23.03.03.047; 14.08.04.010--Not Available
Metabolic syndrome14.11.01.032; 24.08.02.014--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Skin burning sensation23.03.03.021; 17.02.06.009--Not Available
Haemorrhage24.07.01.002--Not Available
Cystoid macular oedema12.02.02.005; 06.04.06.010--Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Angiopathy24.03.02.007--Not Available
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages